MARKET COMPOSITE
HSKA - Heska Corp.
Price
$0.00
+ 0.00 (0.00%)
Heska Corporation manufactures, sells, and markets veterinary diagnostic and specialty products for canine and feline healthcare markets in the United States, Canada, Europe, and internationally. The company's Core Companion Animal segment offers Element DC and Element DC5x veterinary chemistry analyzers for blood chemistry and electrolyte analysis; Element HT5 and HemaTrue veterinary hematology analyzers to measure blood cell and platelet count, and hemoglobin levels; Element POC blood gas and electrolyte analyzers; Element i immunodiagnostic analyzers; Element COAG veterinary analyzers; and IV infusion pumps. It also provides digital radiography hardware and mobile digital radiography products, as well as ultrasound systems; Cloudbank, a Web-based image storage solution; ViewCloud and HeskaView, a picture archival and communications system for Cloudbank; point-of-care heartworm diagnostic test products for dogs and cats; Tri-Heart Plus chewable tablets for the treatment of canine heartworm infection, and treatment and control of ascarid and hookworm infections; and allergy products and services, including ALLERCEPT definitive allergen panels, and therapy shots or drops. The company's Other Vaccines and Pharmaceuticals segment offers a line of bovine vaccines; biological and pharmaceutical products for other animal health companies; and various turnkey services comprising research, licensing, production, labeling, and packaging, as well as provides validation support and distribution services. It sells its products to veterinarians through a field organization, a telephone sales force, and third party distributors; and trade shows, print advertising, and other distribution relationships. The company was formerly known as Paravax, Inc. and changed its name to Heska Corporation in 1995. Heska Corporation was founded in 1988 and is based in Loveland, Colorado.
Financials
Quarterly financials
(USD)Mar 2023Q/Q
Revenue62.4MM-6%
Gross Profit27.4MM-2%
Cost Of Revenue35MM-9%
Operating Income-10.4MM-
Operating Expenses37.8MM+24%
Net Income-10.1MM-
R&D3.1MM+19%
G&A22.3MM+46%
Marketing12.4MM-1%
Amortization2.5MM-23%
Interest Expense939K-19%
Stock Chart
leak data

Short Volume Ratio = Short Volume / All Volume. Source of Short Volume data comes from 

Finra

Moving Average Convergence/Divergence oscillator (MACD) is one of the simplest and most effective momentum indicators available.

Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. RSI oscillates between zero and 100. According to Wilder, RSI is considered overbought when above 70 and oversold when below 30.

Stock news

    By Steven Ralston, CFA NYSE:VNRX READ THE FULL VNRX RESEARCH REPORT Highlights of Annual Capital Markets Day On May 11, 2023, VolitionRx (NYSE:VNRX) conducted the company’s Annual Capital Markets Day. The presentations included the current status and prospects of Nu.Q NETs and Nu.Q Vet , the two pillars of the company that are entering the commercialization phase. Volition’s blood tests (assays)

    S&P Dow Jones Indices will make the following changes to the S&P SmallCap 600 effective prior to the opening of trading on Wednesday, June 14:

    Fred Alger Management, an investment management company, released its “Alger Small Cap Focus Fund” first quarter 2023 investor letter. A copy of the same can be downloaded here. In the first quarter, the fund underperformed the Russell 2000 Growth Index. The Health Care and Energy sectors contributed to the fund’s relative performance in the quarter, […]

    Heska (HSKA) delivered earnings and revenue surprises of -46.88% and 7.10%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?

    Heska Corporation (NASDAQ: HSKA; "Heska" or "Company"), a leading global provider of advanced veterinary diagnostic and specialty products, reported financial results for its first quarter ended March 31, 2023.

    Heska Corporation (NASDAQ: HSKA; "Heska" or the "Company"), a leading global provider of advanced veterinary diagnostic and specialty solutions, announces its 2023 Annual Meeting of Stockholders. The virtual event is scheduled for 9 a.m. MT / 11 a.m. ET on Wednesday, May 3, 2023. Stockholders of record as of March 6, 2023, are entitled to notice of, participate in and vote at, the annual meeting. All stockholders are encouraged to vote on the proposed matters before the Annual Meeting by proxy a

    The worst result, after buying shares in a company (assuming no leverage), would be if you lose all the money you put...

    Why Heska Stock Is On Fire Today04-03-2023 15:31:40 PM

    Mars, the fourth-largest privately held company in the U.S., has agreed to buy the pet diagnostics and specialty products company Heska (NASDAQ: HSKA) for $120 per share. This buyout agreement represents a 23% premium relative to Heska's closing price last Friday. Through this deal, Mars will gain Heska's rapidly growing suite of pet diagnostics products, which are quickly becoming an integral part of the veteinary practices across a wide range of geographies.

    Mars Inc is buying veterinary equipment firm Heska Corp in a $1.3-billion deal as the maker of Pedigree dog food looks to expand its animal diagnostics business. In a joint statement issued on Monday, Mars said it would pay $120 per share to Heska's shareholders, which is a premium of 22.9% over its last close. Shares of Heska were up 19.8% to $116.6, in early morning trading.

    Mars, Incorporated ("Mars"), and Heska Corporation (NASDAQ: HSKA) ("Heska") today announced that they have entered into a definitive agreement under which Mars will acquire Heska, a global provider of advanced veterinary diagnostic and specialty products for $120.00 per share. The transaction price represents a premium of approximately 38% over Heska's 60-calendar day volume weighted average price and a premium of approximately 23% over Heska's closing stock price as of March 31, 2023. The agree